AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

SLU-PP-332 research guide

Synthetic small-molecule estrogen-related receptor (ERR) agonist

SLU-PP-332 research explained through ERR receptor assays, muscle-cell measurements and mouse metabolic studies, without treating preclinical findings as product claims.

AUS Peptide Supply editorial team
SLU PP 332

01 · Identity

What the name identifies

SLU-PP-332 is a synthetic small molecule characterised as an agonist of the estrogen-related nuclear receptors ERRα, ERRβ and ERRγ. The original study reported the greatest potency at ERRα among the three tested subtypes. It is not a peptide or a growth-hormone analogue. Its research context concerns receptor-regulated metabolic programmes, so the exact ERR target and experimental model should accompany a claim.

02 · Evidence position

What the literature can support

The selected primary papers report receptor assays, skeletal-muscle-cell experiments and mouse studies. Cellular respiration, gene expression and whole-animal endpoints are different levels of evidence. The term exercise mimetic describes the authors’ experimental comparison; it does not establish an exercise substitute or a benefit for people. The papers do not verify independently supplied catalogue material.

03 · Study-level map

Evidence and its limits

Preclinical

Which receptor and cellular findings were reported?

The 2023 paper characterised SLU-PP-332 across ERRα, ERRβ and ERRγ assays and reported increased mitochondrial function and respiration in a skeletal-muscle cell line. Mouse experiments investigated oxidative muscle characteristics and exercise endurance.

Limit: The cell and animal systems define the observations. A name on a vial does not establish comparable receptor activity, exposure or performance.

Preclinical

What did the metabolic follow-up examine?

The 2024 paper assessed SLU-PP-332 in diet-induced-obese and ob/ob mouse models. It reported changes in energy expenditure and fatty-acid oxidation, accompanied by reduced fat-mass accumulation and improved insulin sensitivity in the tested models.

Limit: This is mouse evidence, not a human trial. Outcomes for the tested preparation should not be generalised to other ERR agonists or commercial powders.

04 · Analytical context

Questions a batch record should answer

  1. 01Do chemical identity measurements match SLU-PP-332 rather than another ERR agonist or a product with a similar code?
  2. 02Are purity, quantitative content and any receptor activity measurements identified separately with their methods and reporting basis?
  3. 03Does the offered material have a defined specification and a traceable relationship to any tested sample or analytical report?

05 · Boundary conditions

What this record does not establish

  • No matching APS analytical report for SLU-PP-332 5mg was verified for this guide.
  • The selected studies do not establish human efficacy, long-term safety or the suitability of a supplier powder for a particular assay.
  • A shared research topic does not establish that distinct small molecules and peptides are interchangeable.

Sources checked

  1. 1.
    SLU-PP-332: ERR agonism, muscle-cell responses and mouse endurance

    Billon et al. — ACS Chemical Biology · 2023 · Primary study

  2. 2.
    A synthetic ERR agonist in mouse metabolic-syndrome models

    Billon et al. — Journal of Pharmacology and Experimental Therapeutics · 2024 · Primary study

Continue through the topic